Prior art

To identify the most relevant prior art for US patent 11041020, I will search the USPTO database for the specific patent number and examine its cited references. I will then analyze each reference for its publication/filing date, brief description, and potential anticipation under 35 U.S.C. § 102.

Search for US Patent 11041020:

Based on the provided patent text, US Patent 11041020 is titled "Methods for the treatment of active Psoriatic Arthritis" and was issued on June 22, 2021, from an application filed on July 20, 2019.

The patent itself lists prior art under "References Cited." I will extract these references and analyze them.

Prior Art Analysis for US Patent 11041020:

The patent text provides a "Prior art date" of 2017-01-30. The legal status is "Active".

To perform a thorough prior art analysis under 35 U.S.C. § 102, each claim would need to be compared in detail against the disclosures of the prior art references. Without access to a comprehensive list of all cited prior art within US11041020 from the provided text, I will identify the references mentioned in the "Prior art keywords" and "Other versions" sections.

From the "Prior art keywords" and "Other versions" sections in the provided text, the following are mentioned:

• US20190338022A1: This is listed as "Other versions" of the patent. This is likely an earlier publication of the same patent application, rather than prior art. Its publication date is 2019-11-07. This would not typically be considered prior art to US11041020 under 35 U.S.C. § 102 as it shares the same priority date and is an earlier publication of the same content.

To identify actual prior art, I would need to access the full list of "References Cited" from the patent document itself, which is not fully provided in the prompt. The provided text, however, defines "prior art" in general terms: "Information known publicly before the effective filing date of a U.S. patent application is called prior art." This includes U.S. patents and published patent applications, foreign patents and applications, journal articles, books, manuals, catalogs, websites, conference proceedings, and scientific papers.

Without the complete list of cited prior art from the patent document, I cannot definitively provide "full citation, publication/filing date, brief description, and which claim(s) it potentially anticipates under 35 U.S.C. § 102" for each reference. However, the patent itself makes general references to existing knowledge and techniques as "known in the art," which would broadly fall under prior art.

For instance, the patent mentions:

• Milstein and Cuello, Nature 305:537 (1983) for methods of making bispecific antibodies.
• Elliott et al., Lancet 344:1125-1127 (1994) regarding low immunogenicity.
• Ausubel, et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., NY, N.Y. (1987-2001); Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor, N.Y. for general recombinant antibody production.
• U.S. Pat. No. 5,627,052, Wen et al., J. Immunol. for SLAM technology.
• Winter (Jones et al., Nature 321:522 (1986); Riechmann et al., Nature 332:323 (1988); Verhoeyen et al., Science 239:1534 (1988)), Sims et al., J. Immunol. 151: 2296 (1993); Chothia and Lesk, J. Mol. Biol. 196:901 (1987), Carter et al., Proc. Natl. Acad. Sci. U.S.A. 89:4285 (1992); Presta et al., J. Immunol. 151:2623 (1993), U.S. for humanization or engineering of antibodies.
• U.S. Pat. Nos. 5,770,428, 5,569,825, 5,545,806, 5,625,126, 5,625,825, 5,633,425, 5,661,016 and 5,789,650 issued to Lonberg et al.; Jakobovits et al. WO 98/50433, Jakobovits et al. WO 98/24893, Lonberg et al. WO 98/24884, Lonberg et al. WO 97/13852, Lonberg et al. for transgenic animals producing human antibodies.
• U.S. Pat. Nos. 5,827,690; 5,849,992; 4,873,316; 5,849,992; 5,994,616; 5,565,362; 5,304,489 for transgenic animals producing antibodies in milk.
• Cramer et al., Curr. Top. Microbol. Immunol. 240:95-118 (1999) and Hood et al., Adv. Exp. Med. Biol. 464:127-147 (1999) for transgenic plants producing antibodies.
• Colligan, Immunology; Kuby, Janis Immunology; Berzofsky, et al., "Antibody-Antigen Interactions," In Fundamental Immunology for affinity determination methods.
• U.S. Pat. Nos. 4,683,195, 4,683,202, 4,800,159, 4,965,188, to Mullis, et al.; U.S. Pat. Nos. 4,795,699 and 4,921,794 to Tabor, et al; U.S. Pat. No. 5,142,033 to Innis; U.S. Pat. No. 5,122,464 to Wilson, et al.; U.S. Pat. No. 5,091,310 to Innis for PCR methods.
• U.S. Pat. Nos. 4,399,216; 4,634,665; 4,656,134; 4,956,288; 5,149,636; 5,179,017 for DHFR markers.
• U.S. Pat. Nos. 5,122,464; 5,770,359; 5,827,739 for GS markers.
• U.S. Pat. Nos. 5,168,062; 5,385,839 for CMV promoter.
• U.S. Pat. Nos. 5,580,734, 5,641,670, 5,733,746, and 5,733,761 for methods of expressing nucleic acids in host cells.
• Katsube, Y., et al., Int J Mol. Med, 1(5):863-868 (1998) for phage display.
• Cunningham and Wells, Science 244:1081-1085 (1989) for alanine-scanning mutagenesis.
• Fisch et al., Bioconjugate Chem., 3:147-153 (1992); Werlen et al., Bioconjugate Chem., 5:411-417 (1994); Kumaran et al., Protein Sci. 6(10):2233-2241 (1997); Itoh et al., Bioorg. Chem., 24(1): 59-68 (1996); Capellas et al., Biotechnol. Bioeng., 56(4):456-463 (1997) for reverse proteolysis.
• Hermanson, G. T., Bioconjugate Techniques, Academic Press: San Diego, Calif. (1996) for methods to introduce activating groups into molecules and preparation of modified human antibodies.
• Wells et al., eds., Pharmacotherapy Handbook, 2nd Edition, Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000) for suitable dosages.
• Gennaro, Ed., Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (Easton, Pa.) 1990; "Remington: The Science & Practice of Pharmacy", 19th ed., Williams & Williams, (1995); and "Physician's Desk Reference", 52nd ed., Medical Economics, Montvale, N.J. (1998) for pharmaceutical compositions and carriers.

These general references represent established scientific and patent knowledge that would contribute to the overall landscape of prior art but do not represent specific anticipatory citations for the particular anti-TNF antibody and treatment regimen claimed in US11041020. Without the actual "References Cited" section from the patent, I cannot provide the specific detailed analysis requested for direct anticipation under 35 U.S.C. § 102.